These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32327168)

  • 21. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    BMC Med; 2013 Mar; 11():80. PubMed ID: 23531108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality.
    Al Kadour A; Marridi WA; Al-Badriyeh D
    Value Health Reg Issues; 2018 Sep; 16():46-60. PubMed ID: 30144775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the quality and trend of reporting of health economic evaluation research in India.
    Karekar S; Shetty Y
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):595-599. PubMed ID: 33249942
    [No Abstract]   [Full Text] [Related]  

  • 25. Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force.
    Hauber AB; González JM; Groothuis-Oudshoorn CG; Prior T; Marshall DA; Cunningham C; IJzerman MJ; Bridges JF
    Value Health; 2016 Jun; 19(4):300-15. PubMed ID: 27325321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Value Health; 2013; 16(2):e1-5. PubMed ID: 23538200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A reporting tool for practice guidelines in health care: the RIGHT statement].
    Chen Y; Yang K; Marušić A; Qaseem A; Meerpohl JJ; Flottorp S; Akl EA; Schünemann HJ; Chan ESY; Falck-Ytter Y; Ahmed F; Barber S; Chen C; Zhang M; Xu B; Tian J; Song F; Shang H; Tang K; Wang Q; Norris SL; ; Labonté VC; Möhler R; Kopp I; Nothacker M; Meerpohl JJ
    Z Evid Fortbild Qual Gesundhwes; 2017 Nov; 127-128():3-10. PubMed ID: 29128430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.
    Hoaglin DC; Hawkins N; Jansen JP; Scott DA; Itzler R; Cappelleri JC; Boersma C; Thompson D; Larholt KM; Diaz M; Barrett A
    Value Health; 2011 Jun; 14(4):429-37. PubMed ID: 21669367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
    Weinstein MC; O'Brien B; Hornberger J; Jackson J; Johannesson M; McCabe C; Luce BR;
    Value Health; 2003; 6(1):9-17. PubMed ID: 12535234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Goettsch WG; Enzing J
    Value Health; 2014; 17(1):1-2. PubMed ID: 24438710
    [No Abstract]   [Full Text] [Related]  

  • 32. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7.
    Eddy DM; Hollingworth W; Caro JJ; Tsevat J; McDonald KM; Wong JB;
    Med Decis Making; 2012; 32(5):733-43. PubMed ID: 22990088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
    Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
    Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons Learned from a Cross-Model Validation between a Discrete Event Simulation Model and a Cohort State-Transition Model for Personalized Breast Cancer Treatment.
    Jahn B; Rochau U; Kurzthaler C; Paulden M; Kluibenschädl M; Arvandi M; Kühne F; Goehler A; Krahn MD; Siebert U
    Med Decis Making; 2016 Apr; 36(3):375-90. PubMed ID: 26476865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.
    Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
    Clin Ther; 2013 Apr; 35(4):356-63. PubMed ID: 23537754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical analysis of the reporting quality of case reports focusing on dental traumatology using the Preferred Reporting Items for Case reports in Endodontics 2020 checklist: A baseline evaluation prior to checklist publication.
    Nagendrababu V; Sarao SK; Berlin-Broner Y; Gopinath VK; Shetty NY; Duncan HF; Abbott PV; Dummer PMH; Levin L
    Dent Traumatol; 2023 Oct; 39(5):483-494. PubMed ID: 37294181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).
    Willis M; Asseburg C; He J
    J Med Econ; 2013 Aug; 16(8):1007-21. PubMed ID: 23718682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
    Kent S; Becker F; Feenstra T; Tran-Duy A; Schlackow I; Tew M; Zhang P; Ye W; Lizheng S; Herman W; McEwan P; Schramm W; Gray A; Leal J; Lamotte M; Willis M; Palmer AJ; Clarke P
    Pharmacoeconomics; 2019 Nov; 37(11):1305-1312. PubMed ID: 31347104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.
    Brazier J; Ara R; Azzabi I; Busschbach J; Chevrou-Séverac H; Crawford B; Cruz L; Karnon J; Lloyd A; Paisley S; Pickard AS
    Value Health; 2019 Mar; 22(3):267-275. PubMed ID: 30832964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.